Effect of corticosteroids on the clinical course of community-acquired pneumonia: A randomized controlled trial

Critical Care

Volumn 15, Issue 2, 2011, Pages

  Fernández Serrano, Silvia ^a   Dorca, Jordi ^a,b   Garcia Vidal, Carolina ^a,c   Fernández Sabé, Núria ^a   Carratalà, Jordi ^a,c   Fernández Agüera, Ana ^a   Corominas, Mercè ^a   Padrones, Susana ^a   Gudiol, Francesc ^a,c   Manresa, Frederic ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CEFTRIAXONE; CEFTRIAXONE PLUS LEVOFLOXACIN; INTERLEUKIN 6; LEVOFLOXACIN; METHYLPREDNISOLONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; ARTIFICIAL VENTILATION; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; COXIELLA BURNETII; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEVER; HAEMOPHILUS INFLUENZAE; HUMAN; LEGIONELLA PNEUMOPHILA; MAJOR CLINICAL STUDY; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; THERAPY EFFECT; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 79952561515     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10103     Document Type: Article

References (27)

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG, . Infectious Diseases Society of America, American Thoracic Society Infectious disease society of America/American Thoracic Society Consensus Guidelines on the management of Community acuired pneumonia in adults. Clin Infect Dis 2007, 44 Suppl 2:S27-S72. 10.1086/511159, 17278083, Infectious Diseases Society of America, American Thoracic Society.
2. File TM. Community-acquired pneumonia. Lancet 2003, 362:1991-2001. 10.1016/S0140-6736(03)15021-0, 14683661.
3. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250. 10.1056/NEJM199701233360402, 8995086.
4. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996, 275:134-141. 10.1001/jama.275.2.134, 8531309.
5. Mortensen E, Coley C, Singer D, Marrie T, Obrosky S, Kappor W, Fine MJ. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team Cohort Study. Arch Intern Med 2002, 162:1059-1064. 10.1001/archinte.162.9.1059, 11996618.
6. Rosón B, Carratalà J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001, 33:158-165.
7. Garcia-Vidal C, Fernández-Sabé N, Carratalà J, Diaz V, Verdaguer R, Dorca J, Gudiol F. Early mortality in patients with community-acquired pneumonia: causes, and risk factors. Eur Respir J 2008, 32:733-739. 10.1183/09031936.00128107, 18508820.
8. Austrian R, Gold J. Pneumococcal bacteriemia with special reference to bacteriemic pneumococcal pneumonia. Ann Intern Med 1964, 60:759-776.
9. Fernández-Serrano S, Dorca J, Coromines M, Carratalà J, Gudiol F, Manresa F. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 2003, 10:813-820. 193876, 12965910.
10. Padrones S, Garcia-Vidal C, Fernández-Serrano S, Fernández A, Masuet C, Carratalà J, Coromines M, Ardanuy C, Gudiol F, Manresa F, Dorca J. Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2010, 29:1243-1251. 10.1007/s10096-010-0993-0, 20567869.
11. Antunes G, Evans SA, Lordan JL, Frew AJ. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002, 20:990-995. 10.1183/09031936.02.00295102, 12412694.
12. Monton C, Torres A, El-Ebiary M, Filella X, Xaubet A, de la Bellacasa JP. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med 1999, 27:1745-1753. 10.1097/00003246-199909000-00008, 10507593.
13. Örtqvist A, Hedlund J, Wretlind B, Carlström A, Kalin M. Diagnostic and prognostic value of Interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995, 27:457-462.
14. Salluh JI, Póvoa P, Soares M, Castro-Faria-Neto HC, Bozza FA, Bozza PT. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care 2008, 12:R76. 10.1186/cc6922, 2481473, 18547407.
15. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi L, Umberger R, Meduri GU. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242-248. 10.1164/rccm.200406-808OC, 15557131.
16. Snijders D, Daniels JMA, de Graaff CS, van der Werf TS, Boersman WG. Efficacy of corticosteroids in community-acquired pneumonia. Am J Respir Crit Care Med 2010, 181:975-982. 10.1164/rccm.200905-0808OC, 20133929.
17. Daifuku R, Movahhed H, Fotheringham N, Bear MB, Nelson S. Time to resolution of morbidity: an endpoint for assessing the clinical cure of community-acquired pneumonia. Respir Med 1996, 90:587-592. 10.1016/S0954-6111(96)90016-5, 8959115.
18. Garcia-Vidal C, Carratalà J, Fernández-Sabé N, Dorca J, Verdaguer R, Manresa F, Gudiol F. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clinical Microbiology and Infection 2009, 15:1033-1038. 10.1111/j.1469-0691.2009.02918.x, 19673961.
19. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007, 30:951-956. 10.1183/09031936.00027607, 17690125.
20. Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, Bartok A, Niosi J, Abramson I, Coffman J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990, 323:1451-1457. 10.1056/NEJM199011223232104, 2233917.
21. Torres A, Dorca J, Zalacaín R, Bello S, El-Ebiary M, Molinos L, Arevalo M, Blanquer J, Celis L, Iriberri M, Prats E, Fernandez R, Irrigaray R, Serra J. Community-Acquired Pneumonia in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 1996, 154:1456-1461.
22. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson D. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. Chest 1993, 104:389-392. 10.1378/chest.104.2.389, 8339624.
23. Monton C, Ewing S, Torres A, El-Ebiary M, Filella X, Rano A, Xaubet A. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 1999, 14:218-220. 10.1034/j.1399-3003.1999.14a37.x, 10489855.
24. Salluh J, Shinotsuka CR, Soares M, Bozza FA, Lapae Silva JR, Tura BR, Bozza PT, Garcia-Vidal C. Cortisol levels and adrenal response in severe community-acquired pneumonia: A systematic review of the literature. J Crit Care 2010, 25:541. 10.1016/j.jcrc.2010.03.004, 20627449.
25. Dehoux MS, Boutten A, Ostinelli J, Seta N, Dombret MC, Crestani B, Deschenes M, Trouillet JL, Aubier M. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994, 150:710-716.
26. Boutten A, Dehoux MS, Seta N, Ostinelli J, Venembre P, Crestani B, Dombert MC, Durand G, Aurbier M. Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1996, 153:336-342.
27. Raño A, Agusti C, Sibila O, Torres A. Associated inflammatory response in pneumonia: role of adjunctive therapy with glucocorticoids. Curr Opin Infect Dis 2006, 19:179-184.